Shanghai Henlius Biotech clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.
- Notable: Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US · ES-SCLC Phase changed: Phase 3 → Phase 2
- Minor: Characteristics of HLX51 · Solid Tumor or Lymphoma Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2023); last known: Not Yet Recruiting
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-18 | NCT07944690 A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in… | Phase 1 | Not Yet Recruiting |
| 2026-11-13 | NCT07935941 A Phase I Study of HLX109 in Healthy Participants | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Early Phase 1 | 1 | |
| Phase 1 | 20 | |
| Phase 1/2 | 2 | |
| Phase 2 | 20 | |
| Phase 2/3 | 6 | |
| Phase 3 | 7 |
Disease areas by active trials, top 10 of 19
Lung Cancer (16) · Non-Small Cell Lung Cancer (NSCLC) (12) · Breast Cancer (9) · Small Cell Lung Cancer (5) · Liver Cancer (4) · Colorectal Cancer (3) · HER2-Positive Cancer (2) · Melanoma (2) · Multiple Myeloma (2) · Triple-Negative Breast Cancer (2)
Get alerts when Shanghai Henlius Biotech's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.